Concise review: XXXX dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine.

@entity1 @entity712 @entity14605 @entity63 @entity19 @entity177 @entity179 @entity65 @entity264
Flow cytometry has been used to detect cells that express high levels of the @entity264 dehydrogenase activity in normal tissues. Such ALDH bright (ALDHbr) cell populations have been sorted from @entity1 cord blood, bone marrow, mobilized peripheral blood, skeletal muscle, and breast tissue and from the rodent brain, pancreas, and prostate. A variety of hematopoietic, endothelial, and mutiltipotential mesenchymal progenitors are enriched in the @entity1 bone marrow, cord, and peripheral blood ALDHbr populations. Multipotential neural progenitors are enriched in rodent brain tissue, and tissue-specific progenitors in the other tissue types. In xenograft models, uncultured @entity1 bone marrow and cord ALDHbr cells home to damaged tissue and protect @entity19 against @entity63 by promoting angiogenesis. Uncultured cord ALDHbr cells also deploy to nonhematopoietic tissues and protect animals in @entity14605 intoxication and chronic @entity177 models. @entity19 ALDHbr cells and cells derived from them in culture protect animals in a chronic @entity179 model. Purifying ALDHbr cells appears to increase their ability to repair tissues in these animal models. Clinical studies suggest that the number of ALDHbr cells present in hematopoietic grafts or circulating in the blood of @entity65 @entity1 is related to clinical outcomes or disease severity. ALDHbr cells have been used to supplement unrelated cord blood transplant and to treat @entity1 with @entity712 and @entity63 . ALDH activity can play several physiological roles in stem and progenitor cells that may potentiate their utility in cell therapy.
